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Abstract
Background: C-MYC, LIN28, OCT4, KLF4, NANOG and SOX2 are stem cell related factors. We detected whether
these factors express in renal cell carcinoma (RCC) tissues to study their correlations with the clinical and
pathological characteristics.
Methods: The expressions of c-MYC, LIN28, SOX2, KLF4, OCT4 and NANOG in 30 RCC patients and 5 non-RCC
patients were detected with quantitative real-time reverse transcription-PCR (qRT-PCR). The data were analyzed
with Wilcoxon signed rank sum test and x2 test.
Results: In RCC group, c-MYC expression was significantly higher in RCC tissues compared with normal tissues (P <
0.05). The expression levels of OCT4, KLF4, NANOG and SOX2 were significantly lower in RCC tissues compared
with normal tissues (P < 0.05). LIN28 expression level was not significant. No difference was observed when it
comes to clinical and pathological characteristics such as gender, age, tumor size, cTNM classification and
differentiation status (P > 0.05). Also the expression levels of all above factors were not significantly changed in
non-RCC group (P > 0.05).
Conclusions: The present analysis strongly suggests that altered expression of several stem cell related factors may
play different roles in RCC. C-MYC may function as an oncogene and OCT4, KLF4, NANOG and SOX2 as tumor
suppressors.
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Background
In 2007, Takahshi et al [1] successfully demonstrated the
induction of pluripotent stem cells from adult human
fibroblast by transfection of four transcription factors:
OCT3/4, SOX2, c-MYC and KLF4. Yu et al [2] developed
a similar method to restore the pluripotency of human
somatic cells by transfecting OCT4, SOX2, NANOG and
LIN28. Recently, we reported that transducting adult rat
cells with lentivirus containing a cocktail of reprogram-
ming factors of OCT4, SOX2, c-MYC and KLF4 could
create rat pluripotent stem cell lines, rather than using len-
tivirus containing OCT4, SOX2, NANOG and LIN28
genes [3]. Besides the potential to induce the pluripotency,
more studies are reported on cancer stem cells because of
their functions to regulate the proliferation, differentiation
and metastasis [4-10]. Bussolati et al [11] found tumor-
initiating stem cells in human RCC; however, few studies
combined all these stem cell related factors together in
pathological specimens of RCC. RCC has increased over
the last decades [12]. Our previous study on stem cells [3]
triggered us to clarify the correlation between the clinical
characteristics and the expressions of c-MYC, LIN28,
KLF4, SOX2, OCT4 and NANOG in RCC, and thereby to
evaluate their existence and roles in RCC.
Methods
Clinical samples of renal cell cancer
Totally, we collected the specimens of 35 patients after
nephrectomy from December 2007 to October 2010 in
Shanghai First People’s Hospital. The specimens were
collected from normal region (outside the range of tumor
or nidus at least 5 cm macroscopically) and tumor/nidus
for each patient. The case matched paired specimens
were classified into the RCC group and non-RCC group
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according to the pathological examination. Finally 30
paired specimens identified as 28 clear cell carcinomas,
1 papillary carcinoma and 1 chromophobe renal carci-
noma, were included in the RCC group, and 5 identified
as 2 urothelial transitional cell cancer, 1 renal harma-
toma, 1 renal tuberculosis and 1 benign tumor in the
non-RCC group. In the RCC group there were 18 male
patients and 12 female patients, with an average age of
60 (40 to 84). Of them 13 were classified as stage I, 13 as
stage II, 4 as stage III in accordance with cTNM of AJCC
(American Joint Committee on Cancer), whereas 6 as
grade I, 15 as grade II and 9 as grade III according to
their differentiation status. There were 4 female patients
and 1 male patient in non-RCC group with the average
age of 55.4 (44 to 68). Two patients diagnosed as urothe-
lial neoplasms were classified as stage III and stage IV
respectively according to cTNM classification and both
of them were in grade I according to their differentiation
status. All the specimens were kept at -80 °C immediately
after surgery until RNA extraction. All patients were
informed and consent. The tissue specimens were con-
firmed by a pathologist.
Total RNA extraction, reverse transcription and qRT-PCR
Total RNA from tissues was extracted using TRizol
reagent (Invitrogen, CA, cat.no: 15596-018). Briefly, total
RNA was extracted from frozen tissues. The tissue was
first ground into powder in mortar with continuous flow
of liquid nitrogen to prevent the tissue from thawing.
About 50-100 mg of the powder was homogenized in
1 mL TRizol reagent. The mixture was kept on ice for
5 min. After centrifuging at 16,200 ×g at 4°C for 15 min,
the supernatant was transferred into another RNase-free
tube along with 0.2 mL chloroform. The tube was shaken
vigorously for 15 sec and kept on ice for 10 min. After
centrifuging at 16,200 ×g at 4°C for 15 min, the super-
natant was transferred into another tube with 0.5 mL iso-
propanol, blended and kept on ice for 5 min. After
centrifuging at 16,200 ×g for 15 min g at 4°C for 10 min,
the supernatant was discarded and the precipitate was
washed with 75% ethanol at 4°C. After centrifuging at
5,600 ×g at 4°C for 6 min, the supernatant was discarded
and the residue was air dried at room temperature. The
RNA pellet was suspended with diethyl pyrocarbonate
treated water at 55°C for 10 min.
RNA quantity and quality were determined by agarose
gel electrophoresis and spectrophotometer at 260 nm.
Reverse transcription for mRNAs was performed using
the PrimeScriptTM RT reagent kit (TaKaRa, Dalian,
China, cat.no: DRR037A). The cDNA template was ampli-
fied by real-time PCR using the SYBR® Premix EX
TaqTM II kit (TaKaRa, Dalian, China, cat.no: DRR081A).
Thermal cycling conditions were as follows: 95°C for
60 sec followed by 35 cycles of 94°C for 10 sec, 59°C for
30 sec and 72°C for 30 sec. After amplification, products
were subjected to 60°C to 95°C, reading plate every 0.4°C
and holding for 1 sec to create a melting curve. Glyceral-
dehyde-3-phosphate-dehydrogenase (GAPDH) mRNA
was used as an internal control to normalize target mRNA
level. PCR products were determined by electrophoresis
on 1% agarose gels containing ethidium bromide.
Primer sequences are as follow: c-myc-forward, 5’-
ACAGCTACGGAACTCTTGTGCGTA-3’, reverse, 5’-
GCCCAAAGTCCAATTTGAGGCAGT-3’; LIN28, for-
ward 5’- GAAGAAGAAATCCACAGCCCTAC-3’, reverse
5’- GATGGTGTGAACCCAAGCCTG-3’; SOX2, forward
5’- CCCATGCACCGCTACGACGTG-3’, reverse 5’-





NANOG, forward 5’- CCCAAAGGCAAACAACC-
CACTTCT-3’, reverse 5’- AGCTGGGTGGAAGAGAA-
CACAGTT-3’. GAPDH was used as an internal control
with the following primers: forward 5’- TCGACAGT-
CAGCCGCATCTTCTTT -3’, reverse 5’- ACCAAATC
CGTTGACTCCGACCTT-3’.
The relative expression fold change of microRNAs and
target mRNAs were calculated by the 2-ΔΔCt method
[13]. All reactions were performed in triplicate.
Statistical Analysis
All tests were analyzed by SAS 8.0 with Wilcoxon
signed rank sum test and x2 test. P-value < 0.05 was
considered to be statistically significant.
Results
Deregulation of c-MYC, LIN28, OCT4, KLF4, NANOG and
SOX2
qRT-PCR analysis demonstrated that in the RCC group
the expressions of stem cell related factors except LIN28
in cancer tissues were significantly changed comparing
with normal tissues (P < 0.05)( Table 1). C-MYC was
significantly up-regulated and KLF4, SOX2, OCT4, and
NANOG were significantly down-regulated (Table 1).
However, the expressions showed no significance in the
non-RCC group (data not shown).
The association between expression level with clinical
and pathological characteristics
We analyzed the data to see if any correlation exists
between the stem cell related factors and clinical charac-
teristics. No expression significance of each stem-cell
related factor in gender, age and tumor size was observed
between RCC and non-RCC group (Table 2, 3).
As for the pathological characteristics such as cTNM
classification and the differentiation status of cancers,
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the expression levels of c-MYC, LIN28, KLF4, SOX2,
OCT4 and NANOG were not significant either( Table
2, 3)
Discussion
Although the number of the RCC cases was limited in
our study, the results are still with interesting implica-
tions. First, in the RCC group the over expression of
c-MYC in cancers was significantly higher than that of
normal tissues (Table 1). No difference of c-MYC was
observed in the non-RCC group. This is in accordance
with Tang’s report [4], and c-MYC is an oncogene asso-
ciated with RCC growth and proliferation by up regulat-
ing target genes like BCL2, CCND1, PCNA, PGK1 and
VEGFA. C-MYC could also induce a somatic cell to
regain pluripotency together with OCT4, SOX2 and
KLF4 [1]. In addition, c-MYC can activate the transcrip-
tion of hTERT that can regulate the activation of telo-
merase [14]. These all indicate that c-MYC plays an
important role in RCC.
Interestingly an important regulatory network involving
c-MYC, let-7 and LIN28/L28b was found recently
[6,15,15-23]. There is a double-negative-feedback loop
between LIN28/IN28b and let-7 where let-7 is able to
repress LIN28/LIN28b by binding to the 3’UTR of LIN28/
LIN28b transcripts and LIN28/LIN28b can also repress
let-7 [15-17]. Another feedback loop is between LIN28
and c-MYC: LIN28/LIN28b up regulates c-MYC by
repressing let-7 [6] and c-MYC transcriptionally activates
both LIN28 and LIN28b [18]. Also, c-MYC is one of the
targets of let-7 [19-21]; in return let-7 can be repressed by
MYC contributing to tumorigeness [22,23]. Besides let-7,
derepression of c-MYC might also contribute to the
repression and activation of diverse miRNAs related to
tumorigeness [22]. The whole regulatory circuits may con-
tribute to the widespread deregulation of miRNAs in
many human malignancies [24]. Although the expression
of LIN28 was not significantly different between normal
specimens and tumors and we see no expression differ-
ence of LIN-28 in non-RCC group either (Table 1), we
think that we need to do more to explore the function of
LIN28/let-7/c-MYC regulatory circle in RCC.
KLF4 is a member of Kruppel like factors, which has a
dual function related to the tumorigeness [25]. KLF4
plays as a tumor suppressor in gastric cancer, colon can-
cer, esophagus cancer, bladder cancer, lung cancer and
pancreatic ductal carcinoma [7,26-28]. Our study shows
that the expression of KLF4 in cancers was significantly
lower than that in normal tissues (Table 1). This suggests
that KLF4 may function as a tumor suppressor in RCC.
Table 1 Significances of deregulated stem cell related
factors
names No of down regulated No of up regulated P value
C-MYC 8 22 0.0010
LIN28 15 15 0.6083
KLF4 25 5 0.0050
SOX2 28 2 < 0.0001
OCT4 26 4 0.0070
NANOG 29 1 < 0.0001
The data were from RCC group. In each paired case matched specimens
(cancer and normal tissue from the same patient), the expression level of
cancer comparing with normal tissue more than 1 is considered up regulated,
or it is down regulated. All experiments are performed three times. P value
< 0.05 was considered statistically significant
Table 2 The expression levels of stem cell related factors





LIN28 KLF4 SOX2 OCT4 NANOG
↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓
Gender
Male 18 11 7 11 7 3 15 2 16 3 15 1 17
Female 12 11 1 4 8 2 10 0 12 1 11 0 12
Age
(years)
≤65 22 17 5 12 10 4 18 2 20 4 18 1 21
>65 8 5 3 3 5 1 7 0 8 0 8 0 8
Tumor size (cm)
≤4 12 9 3 7 5 3 9 1 11 3 9 1 11
>4 18 13 5 8 10 2 16 1 17 1 17 0 18
cTNM
I 13 10 3 8 5 2 11 1 12 2 11 1 12
II 13 9 4 6 7 2 11 1 12 1 12 0 13
III 4 3 1 1 3 1 3 0 4 1 3 0 4
Differentiation
Well 6 5 1 3 3 1 5 0 6 0 6 0 6
Moderate 15 12 3 7 8 3 12 2 13 2 13 1 14
Poor 9 5 4 5 4 1 8 0 9 2 7 0 9
The data were from RCC group. ↑represent in each paired case matched
specimens (cancer and normal tissue from the same patient), the expression
level of cancer comparing with normal tissue is more than 1, or it is down
regulated and it is represented by ↓. All experiments are performed three
times.
Table 3 Significances of deregulated stem cell related
factors in terms of clinical and pathological
characteristics
Items P value
Gender Age Tumor size cTNM Differentiation
C-MYC 0.0683 0.4263 0.8684 0.8141 0.2020
LIN28 0.1427 0.4169 0.4637 0.1936 0.7976
KLF4 1.0000 0.7166 0.3255 0.7272 0.7308
SOX2 0.2399 0.3855 0.7689 0.6767 0.8371
OCT4 0.5178 0.2028 0.1313 0.8784 0.2274
NANOG 0.4142 0.5465 0.2207 0.3106 0.8864
The data were from RCC group. Expression levels were combined with clinical
and pathological characteristics with Wilcoxon signed rank sum test and x2
test. P value < 0.05 was considered statistically significant.
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Lu [10] reported that SOX2 was over-expressed in
human squamous cell lung tumors and some adenocarci-
nomas. Sanada et al [29] saw an increasing expression of
SOX2 with the progression of pancreatic carcinoma. In
our study, SOX2 was lower in cancers compared with
normal tissues. Its expression level was significantly
down regulated in RCC (Table 1). Given that some bio-
marker like KLF4 mentioned above may function totally
reversely in different cancers [25], we think it is possible
that SOX2 may be a tumor suppressor in RCC.
OCT4 is essential to reprogram somatic ells to regain
pluripotency [30]. Looijenga [31] found that OCT4 is
positive in RCC, but its expression is quite low compar-
ing with germ cell tumor. So it is in accordance with the
theory that the amount of cancer stem cell is quite small
in tumor and even less in solid tumor [32,33]. As for
NANOG, Yu [2] achieved a significant breakthrough in
reprogramming somatic cells back to pluripotent stem
cells. As reported by Ezeh [8] and Hart [9], NANOG
expressed in embryonal carcinomas, seminomas and
breast cancer, and could be a valuable marker of tumori-
geness. According to the report of Bussolati et al [11],
the RCC stem cells they identified were OCT4 and
NANOG sharply positive, but we saw some interesting
results about the above-mentioned two factors, they both
were significantly down regulated in RCC (Table 1). Also
we did not see any significant correlation between their
expression and clinical and pathological characteristics
(Table 2, 3). We thought there were several reasons con-
tributing to this. First, OCT4 and NANOG are not speci-
fic biomarkers for RCC or they do not play dominant
roles in the tumorigeness of RCC, but according to Bus-
solati’s [11] report, OCT4 and NANOG are expressed in
tumor-initiating CD105+ stem cells in human renal car-
cinomas. Cells from CD105+ clones cultured in epithelial
or endothelial differentiating medium for 2 weeks
acquired the expression of differentiative markers and
lost stem cell markers. So this may not be the main rea-
son for our result. Second, most cells in cancer are sub-
groups of cancer stem cells which only express a narrow
range of stem cell related factors. So only a tiny part of
these cells can present the whole characters of stem cell.
Last but not the least, the cancer stem cell is really rare
in the tumor as mentioned previously [32,33]. Also,
OCT4 and NANOG might function as tumor suppres-
sors in RCC indeed. We think Bussolati’s [11] positive
findings of OCT4 and NANOG in RCC stem cells is
because that they isolated CD105+ cells from other ones
just like a kind of purification. According to Moreira’s
[34] report, in lung cancers, stem cell markers are
expressed with different patterns seen for different histo-
logical types and degrees of differentiation, considering
that our RCC specimens were restricted to clear cell RCC
(28 in 30), we still cannot eliminate OCT4 and NANOG
as non-potential biomarkers for RCC and more compre-
hensive studies are needed to elucidate their importance.
Although all stem cell related factors except LIN28 were
significantly deregulated (Table 1), there were no signifi-
cant results in terms of clinical and pathological character-
istics (Table 2, 3). There are some reasons contributing to
this. Fist, we think that if cancer stem cells do exist in
RCC, they could just initiate the carcinogenesis progress,
and were not dependable after initiation. Second, our
patient number is limited and we don’t have follow-up
information. Like Zhang’s [35] report about OCT4 in lung
adenocarcinoma, there were no significant findings in
terms of clinical and pathological characteristics, but when
they combined OCT4 expression level with the follow-up
information of 5 years, OCT4 was found to be the inde-
pendent prognostic factor. So this may be one of draw-
backs in our study. But our study first combined all the six
stem cell related factors with tissue specimens. This will
provide us with useful information to explore more about
the function of the six stem cell related factors in RCC.
Conclusions
In conclusion, the results of our analysis of stem cell
related factors between RCC and non-RCC groups, suggest
that deregulation of these factors may be one of the onco-
genic mechanisms underlying RCC pathogenesis. Espe-
cially, the expression of c-MYC, KLF4, OCT4, NANOG
and SOX2 implies that these 5 factors are involved in carci-
nogenesis and progression of RCC, and probably there are
RCC cancer stem cells existing in renal carcinoma. More
data are needed to confirm our hypothesis.
Abbreviations
RCC: renal cell carcinoma; qRT-PCR: quantitative real-time reverse
transcription-PCR; GAPDH: glyceraldehyde-3-phosphate-dehydrogenase.
Acknowledgements
This work was supported by the following grants and foundations:
Innovation Program of Shanghai Municipal Education Commission (Grant
No: 09ZZ25) and Program of Science and Technology Commission of
Shanghai Municipality (Grant No: 09411968100). We will appreciate Ren
Jiangtao, Cheng Lu and Hong Yan for their help in our experiments.
Author details
1Department of Urology, Shanghai First People’s Hospital, School of
Medicine, Shanghai Jiaotong University, Shanghai 200080, China. 2Laboratory
of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Cell
Bank, Stem Cell Bank, Shanghai Institutes for Biological Sciences, Chinese
Academy of Sciences, Shanghai 200031, China.
Authors’ contributions
YL and CZ carried out all the experimental studies. YL drafted the
manuscript and performed the statistical analysis. BY and LZ collected all
specimens. JF conceived of the study and participated in its design and
coordination. JF, LX and SX helped to draft the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Liu et al. World Journal of Surgical Oncology 2011, 9:121
http://www.wjso.com/content/9/1/121
Page 4 of 5
Received: 27 July 2011 Accepted: 7 October 2011
Published: 7 October 2011
References
1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K,
Yamanaka S: Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 2007, 131:861-872.
2. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S,
Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al: Induced pluripotent stem
cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
3. Liao J, Cui C, Chen S, Ren J, Chen J, Gao Y, Li H, Jia N, Cheng L, Xiao H,
Xiao L: Generation of induced pluripotent stem cell lines from adult rat
cells. Cell Stem Cell 2009, 4:11-15.
4. Tang SW, Chang WH, Su YC, Chen YC, Lai YH, Wu PT, Hsu CI, Lin WC,
Lai MK, Lin JY: MYC pathway is activated in clear cell renal cell
carcinoma and essential for proliferation of clear cell renal cell
carcinoma cells. Cancer Lett 2009, 273:35-43.
5. Guo Y, Chen Y, Ito H, Watanabe A, Ge X, Kodama T, Aburatani H:
Identification and characterization of lin-28 homolog B (LIN28B) in
human hepatocellular carcinoma. Gene 2006, 384:51-61.
6. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S,
O’Sullivan M, Lu J, Phillips LA, Lockhart VL, et al: Lin28 promotes
transformation and is associated with advanced human malignancies.
Nat Genet 2009, 41:843-848.
7. McConnell BB, Ghaleb AM, Nandan MO, Yang VW: The diverse functions of
Kruppel-like factors 4 and 5 in epithelial biology and pathobiology.
Bioessays 2007, 29:549-557.
8. Ezeh UI, Turek PJ, Reijo RA, Clark AT: Human embryonic stem cell genes
OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma
and breast carcinoma. Cancer 2005, 104:2255-2265.
9. Hart AH, Hartley L, Parker K, Ibrahim M, Looijenga LH, Pauchnik M,
Chow CW, Robb L: The pluripotency homeobox gene NANOG is
expressed in human germ cell tumors. Cancer 2005, 104:2092-2098.
10. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL, Onaitis MW:
Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One
2010, 5:e11022.
11. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G: Identification of a
tumor-initiating stem cell population in human renal carcinomas. Faseb J
2008, 22:3696-3705.
12. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK: Rising incidence
of small renal masses: a need to reassess treatment effect. J Natl Cancer
Inst 2006, 98:1331-1334.
13. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25:402-408.
14. Liu X, Dakic A, Chen R, Disbrow GL, Zhang Y, Dai Y, Schlegel R: Cell-
restricted immortalization by human papillomavirus correlates with
telomerase activation and engagement of the hTERT promoter by Myc.
J Virol 2008, 82:11568-11576.
15. Bussing I, Slack FJ, Grosshans H: let-7 microRNAs in development, stem
cells and cancer. Trends Mol Med 2008, 14:400-409.
16. Piskounova E, Viswanathan SR, Janas M, LaPierre RJ, Daley GQ, Sliz P,
Gregory RI: Determinants of microRNA processing inhibition by the
developmentally regulated RNA-binding protein Lin28. J Biol Chem 2008,
283:21310-21314.
17. Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R, Wulczyn FG: A
feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation
during neural stem-cell commitment. Nat Cell Biol 2008, 10:987-993.
18. Viswanathan SR, Daley GQ: Lin28: A microRNA regulator with a macro
role. Cell 2010, 140:445-449.
19. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T: Impaired microRNA
processing enhances cellular transformation and tumorigenesis. Nat
Genet 2007, 39:673-677.
20. He XY, Chen JX, Zhang Z, Li CL, Peng QL, Peng HM: The let-7a microRNA
protects from growth of lung carcinoma by suppression of k-Ras and c-
Myc in nude mice. J Cancer Res Clin Oncol 2009, 136:1023-1028.
21. Wong TS, Man OY, Tsang CM, Tsao SW, Tsang RK, Chan JY, Ho WK, Wei WI,
To VS: MicroRNA let-7 suppresses nasopharyngeal carcinoma cells
proliferation through downregulating c-Myc expression. J Cancer Res Clin
Oncol 2011, 137:415-422.
22. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV,
Thomas-Tikhonenko A, Mendell JT: Widespread microRNA repression by
Myc contributes to tumorigenesis. Nat Genet 2008, 40:43-50.
23. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ,
Dunn SP, Krueger LJ: MicroRNA let-7a down-regulates MYC and reverts
MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007,
67:9762-9770.
24. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-
Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression
profiles classify human cancers. Nature 2005, 435:834-838.
25. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID,
Townes TM, Paterson AJ, et al: Induction of KLF4 in basal keratinocytes
blocks the proliferation-differentiation switch and initiates squamous
epithelial dysplasia. Oncogene 2005, 24:1491-1500.
26. Evans PM, Liu C: Roles of Krupel-like factor 4 in normal homeostasis,
cancer and stem cells. Acta Biochim Biophys Sin (Shanghai) 2008,
40:554-564.
27. Zhou Y, Hofstetter WL, He Y, Hu W, Pataer A, Wang L, Wang J, Yu L, Fang B,
Swisher SG: KLF4 inhibition of lung cancer cell invasion by suppression
of SPARC expression. Cancer Biol Ther 2010, 9:507-513.
28. Zammarchi F, Morelli M, Menicagli M, Di Cristofano C, Zavaglia K,
Paolucci A, Campani D, Aretini P, Boggi U, Mosca F, et al: KLF4 is a novel
candidate tumor suppressor gene in pancreatic ductal carcinoma. Am J
Pathol 2011, 178:361-372.
29. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y:
Histopathologic evaluation of stepwise progression of pancreatic
carcinoma with immunohistochemical analysis of gastric epithelial
transcription factor SOX2: comparison of expression patterns between
invasive components and cancerous or nonneoplastic intraductal
components. Pancreas 2006, 32:164-170.
30. Jaenisch R, Young R: Stem cells, the molecular circuitry of pluripotency
and nuclear reprogramming. Cell 2008, 132:567-582.
31. Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van
Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H,
et al: POU5F1 (OCT3/4) identifies cells with pluripotent potential in
human germ cell tumors. Cancer Res 2003, 63:2244-2250.
32. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med
1997, 3:730-737.
33. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and
cancer stem cells. Nature 2001, 414:105-111.
34. Moreira AL, Gonen M, Rekhtman N, Downey RJ: Progenitor stem cell
marker expression by pulmonary carcinomas. Mod Pathol 2010,
23:889-895.
35. Zhang X, Han B, Huang J, Zheng B, Geng Q, Aziz F, Dong Q: Prognostic
significance of OCT4 expression in adenocarcinoma of the lung. Jpn J
Clin Oncol 2010, 40:961-966.
doi:10.1186/1477-7819-9-121
Cite this article as: Liu et al.: Comprehensive analysis of clinical
significance of stem-cell related factors in renal cell cancer. World
Journal of Surgical Oncology 2011 9:121.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liu et al. World Journal of Surgical Oncology 2011, 9:121
http://www.wjso.com/content/9/1/121
Page 5 of 5
